MedTrace Logo

Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial

NCT04678739 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 205

Last updated 2021-04-02

No results posted yet for this study

Summary

This randomized clinical trial was designed and intended to evaluate the efficacy of Remdesivir and Tocilizumab as a treatment for severe Acute Respiratory Distress Syndrome (ARDS) caused by Coronavirus disease 2019 (COVID-19). Our aim is to find the best option for the treatment and management of ARDS in COVID-19 patients.

Conditions

  • Covid19
  • Covid-19 ARDS

Interventions

DRUG

Remdesivir

Remdesivir 100 IV Infusion as a lyophilized powder

DRUG

Tocilizumab

Actemra IV Infusion

Sponsors & Collaborators

  • First Affiliated Hospital Xi'an Jiaotong University

    collaborator OTHER

  • Cox's Bazar 250 Bed District Sadar Hospital

    collaborator UNKNOWN

  • Chattogram General Hospital

    collaborator OTHER_GOV

  • M Abdur Rahim Medical College and Hospital

    lead OTHER_GOV

Principal Investigators

  • Abu Taiub Mohammed Mohiuddin Chowdhury, MBBS, MD · First Affiliated Hospital Xi'an Jiaotong University

  • Akter Kamal, MD, PhD · M Abdur Rahim Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-15
Primary Completion
2021-01-30
Completion
2021-02-10

Countries

  • Bangladesh

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04678739 on ClinicalTrials.gov